Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ILLUMINA, INC.ILMN · Entity 3137 | SVP, Chief Financial Officer | March 05, 2024 | March 07, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ILLUMINA, INC.
Report date March 05, 2024 · Filed March 07, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 24,478 |
Reported balance
After 2024-03-05 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2024-03-05 · Grant · Acquired 5,569 · Balance 24,478 F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2025, February 15, 2026, February 15, 2027, and February 15, 2028, subject to awardee's continuing status as a service provider on such dates. F2: Balance includes 132 shares acquired through Employee Stock Purchase Plan. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2027-01-03 | Direct | 6,497 |
Reported balance
After 2024-03-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-03-05 · Grant · Acquired 6,497 · Balance 6,497 F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. |
| Performance SharesSEC Table II · derivative / convertible security · Expires 2027-01-03 | Direct | 6,497 |
Reported balance
After 2024-03-05 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-05 · Grant · Acquired 6,497 · Balance 6,497 F4: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. |
Filing footnotes · ownership attribution and instrument terms
F1: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2025, February 15, 2026, February 15, 2027, and February 15, 2028, subject to awardee's continuing status as a service provider on such dates.
F2: Balance includes 132 shares acquired through Employee Stock Purchase Plan.
F3: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates.
F4: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
BIOLIFE SOLUTIONS INC
Report date October 06, 2026 · Filed October 09, 2026
Section 16 reporting ended · disclosed 2026-10-09. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-10-06 transaction · row 1
1 source rowRow 1 · 2026-10-06 · Disposition to issuer · Disposed 53,156 · Balance 0 F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. |
Filing footnotes · ownership attribution and instrument terms
F1: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 06, 2026 Filed Oct 9, 2026 01:59 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | Disposition to issuerCommon Stock | 53,156 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001193125-26-418328 · ownership.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · price: Reflects the disposition of shares of common stock ("Common Stock") of BioLife Solutions, Inc. (the "Registrant") in connection with the consummation on October 6, 2026 of the merger of Bravo Merger Sub I, Inc., a Delaware corporation ("Merger Sub 1") with and into the Registrant (the "First Merger"), pursuant to the Agreement and Plan of Merger, dated as of July 21, 2026 (the "Merger Agreement"), by and among the Registrant, Repligen Corporation, a Delaware corporation ("Repligen"), Merger Sub 1 and Bravo Merger Sub II, LLC, a Delaware limited liability company. At the effective time of the First Merger (the "First Merger Effective Time"), each outstanding share of Common Stock was converted into the right to receive $11.25 in cash and 0.1442 shares of Repligen common stock, in each case subject to the terms and conditions of the Merger Agreement. Read SEC document |
| February 24, 2026 Filed Feb 26, 2026 22:55 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 8,170 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-26-012468 · wk-form4_1772146503.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,156 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the first anniversary of the vesting date of January 2, 2026 Read SEC document |
| October 24, 2025 Filed Oct 28, 2025 21:14 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,666 | $28.99 | $48,297.34 |
DisclosureSEC source: 0001628280-25-046841 · wk-form4_1761686094.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,986 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024. Read SEC document |
| October 16, 2025 Filed Oct 20, 2025 21:03 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | SaleCommon Stock | 1,334 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-045544 · wk-form4_1760994234.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 46,652 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 (c) trading plan adopted by the reporting person effective as of 12-13-2024. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.99 to $29.00, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 18, 2025 Filed Mar 20, 2025 23:07 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 6,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-25-014181 · wk-form4_1742512061.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,986 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the measurement date of 01-02-2025. Read SEC document |
| March 08, 2024 Filed Mar 13, 2024 01:44 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 11,264 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-24-010749 · wk-form4_1710294260.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,110 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan (the "2023 Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009050 · form4.xml · derivative · entry 3 GOSWAMI JOYDEEP · CIK 0001533115 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock · 6,497 shares Expires 2027-01-03 F4 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F4 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending January 3, 2027. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending January 3, 2027, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009050 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,497 Underlying: Common Stock · 6,497 shares Expires 2027-01-03 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's three-year average operating margin for fiscal years 2024-2026 with vesting on January 3, 2027 . The number of shares issued will range from 0% to 200% of the amount specified above, based on the Company's actual three-year average operating margin for fiscal years 2024-2026 , relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| March 05, 2024 Filed Mar 7, 2024 22:35 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 5,569 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-24-009050 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,478 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 15, 2025, February 15, 2026, February 15, 2027, and February 15, 2028, subject to awardee's continuing status as a service provider on such dates. F2 · balance_after: Balance includes 132 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| November 05, 2023 Filed Nov 8, 2023 00:54 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,887 | $112.84 | $212,929.08 |
DisclosureSEC source: 0001127602-23-026966 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP, Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,777 Read SEC document |
| November 01, 2023 Filed Nov 3, 2023 21:10 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 577 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-036781 · wk-form4_1699045814.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,846 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| October 05, 2023 Filed Oct 10, 2023 21:41 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 165 | $139.43 | $23,005.95 |
DisclosureSEC source: 0001127602-23-025721 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,664 F1 · balance_after: Balance includes 103 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| October 01, 2023 Filed Oct 10, 2023 21:27 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 422 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001628280-23-034207 · wk-form4_1696973215.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,269 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of cash director fees at the last closing price as of the date of grant. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008581 · form4.xml · derivative · entry 3 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,045 Underlying: Common Stock · 6,045 shares Expires 2025-12-28 F3 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F3 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's relative total shareholder return for the fiscal year ending December 28, 2025. The number of shares issued will range from 0% to 175% of the amount specified above, based on the company's relative total shareholder return for the fiscal year ending December 28, 2025, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,030 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008581 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,030 Underlying: Common Stock · 4,030 shares Expires 2024-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 16:19 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 10,074 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-008581 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,726 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2023, November 5, 2024, November 5, 2025, and November 5, 2026, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:38 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 4,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006828 · form4.xml · derivative · entry 3 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 4,696 shares Expires 2023-01-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:38 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,640 | $202.84 | $332,657.60 |
DisclosureSEC source: 0001127602-23-006828 · form4.xml · nonDerivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,652 Read SEC document |
| February 21, 2023 Filed Feb 23, 2023 22:38 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 4,696 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-23-006828 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,292 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 94% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on February 5, 2020. F2 · balance_after: Balance includes 14 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| January 03, 2023 Filed Jan 19, 2023 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 10,187 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-23-001265 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,847 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| November 05, 2022 Filed Nov 8, 2022 22:04 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 638 | $217.19 | $138,567.22 |
DisclosureSEC source: 0001127602-22-025125 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,582 Read SEC document |
| October 05, 2022 Filed Oct 6, 2022 20:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 165 | $218.52 | $36,055.80 |
DisclosureSEC source: 0001127602-22-023767 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,220 Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 280 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-018514 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,660 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document |
| July 01, 2022 Filed Jul 7, 2022 00:00 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 369 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-016763 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,380 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document |
| June 01, 2022 Filed Jun 4, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 343 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-014308 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,011 F1 · price: The shares of restricted stock reported herein were issued to the reporting person in lieu of a portion of directors fees at the last closing price as of the date of grant. Read SEC document |
| May 06, 2022 Filed May 11, 2022 00:02 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 14,730 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-22-011806 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,668 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan (the "Plan") and fully vests on the first anniversary of the grant date. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 6,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008114 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,246 Underlying: Common Stock · 6,246 shares Expires 2024-12-29 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 29, 2024. The number of shares issued will range from 0% to 200% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending December 29, 2024, relative to pre-defined objectives, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| March 01, 2022 Filed Mar 3, 2022 23:31 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 2,082 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-008114 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,385 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2022, November 5, 2023, November 5, 2024, and November 5, 2025, subject to the awardee's continuing status as a service provider on such dates. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionPerformance Shares · Derivative | 3,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006621 · form4.xml · derivative · entry 3 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,979 shares Expires 2022-01-02 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on October 7, 2019. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on October 7, 2019. F1 · derivative.exercise_date: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on October 7, 2019. Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 1,521 | $319.86 | $486,507.06 |
DisclosureSEC source: 0001127602-22-006621 · form4.xml · nonDerivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,303 Read SEC document |
| February 22, 2022 Filed Feb 24, 2022 22:34 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Exercise / conversionCommon Stock | 3,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-22-006621 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,824 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: Represents shares of stock awarded as a result of the Company achieving at least 100% of the applicable performance criteria pursuant to the reporting person's grant of performance share units on October 7, 2019. F2 · balance_after: Balance includes 56 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| November 05, 2021 Filed Nov 9, 2021 22:01 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 264 | $408.14 | $107,748.96 |
DisclosureSEC source: 0001127602-21-028724 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,789 Read SEC document |
| October 05, 2021 Filed Oct 7, 2021 20:54 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 115 | $387.98 | $44,617.70 |
DisclosureSEC source: 0001127602-21-026804 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,053 F1 · balance_after: Balance includes 56 shares acquired through Employee Stock Purchase Plan. Read SEC document |
| October 01, 2021 Filed Oct 8, 2021 00:01 UTC | BIOLIFE SOLUTIONS INC BLFS · Entity 4614 | GrantCommon Stock | 2,938 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001437749-21-023465 · rdgdoc.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,938 F1 · price: The restricted stock was granted pursuant to the BioLife Solutions 2013 Performance Incentive Plan and vests on the twelve-month anniversary of the grant date. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,140 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005283 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,140 Underlying: Common Stock · 4,140 shares Expires 2023-12-31 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending December 31, 2023. The number of shares issued will range from 0% to 175% of the amount specified above, based on the Company's actual earnings per share for the fiscal year ending December 31,2023, relative to pre-defined objectives, subject to awardee's continuing to be a service provider on such dates. Read SEC document |
| February 09, 2021 Filed Feb 11, 2021 23:45 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,380 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-21-005283 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,112 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of November 5, 2021, November 5, 2022, November 5, 2023, and November 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| November 05, 2020 Filed Nov 9, 2020 22:37 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 145 | $311.72 | $45,199.40 |
DisclosureSEC source: 0001127602-20-028498 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,732 Read SEC document |
| October 05, 2020 Filed Oct 7, 2020 20:52 UTC | ILLUMINA, INC. ILMN · Entity 3137 | Tax withholdingCommon Stock | 115 | $316.17 | $36,359.55 |
DisclosureSEC source: 0001127602-20-026676 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,877 Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 4,995 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004398 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,995 Underlying: Common Stock · 4,995 shares Expires 2023-01-01 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 1, 2023. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 1, 2023, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| February 05, 2020 Filed Feb 7, 2020 22:51 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,665 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-20-004398 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,992 F1 · shares: Grant of restricted stock units shall vest as follows: 25% of the shares subject to the award shall vest on each of February 5, 2021, February 5, 2022, February 5, 2023 and February 5, 2024, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:42 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantPerformance Shares · Derivative | 3,979 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030346 · form4.xml · derivative · entry 2 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,979 Underlying: Common Stock · 3,979 shares Expires 2022-01-02 F2 · derivative.exercise_price: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. F2 · derivative.exercise_date: Each performance stock unit represents a contingent right to receive one share of common stock based on the Company's earnings per share for the fiscal year ending January 2, 2022. The number of shares issued will range from 0% to 150% of the amount specified above, based on the company's actual earnings per share for the fiscal year ending January 2, 2022, relative to pre-defined objectives, subject to awardee's continuing status as a service provider on such dates. Read SEC document |
| October 07, 2019 Filed Oct 9, 2019 22:42 UTC | ILLUMINA, INC. ILMN · Entity 3137 | GrantCommon Stock | 1,327 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-19-030346 · form4.xml · nonDerivative · entry 1 GOSWAMI JOYDEEP · CIK 0001533115 · SVP Corp Business Development 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,327 F1 · shares: Grant of restricted stock units with 25% of the shares subject to the award vesting on each of the first, second, third and fourth anniversaries of the date of grant, subject to the awardee's continuing to be a service provider on such dates. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.